Cogent Biosciences (NASDAQ: COGT) released its earnings results on January 31, 2024, reporting a loss of $0.73 per share for the quarter. This result fell short of analysts’ expectations, which had anticipated a loss of $0.51 per share, marking a difference of $0.22.
The company’s stock opened at $36.55 on the same day. Over the past year, Cogent Biosciences has experienced a significant range in its stock price, with a twelve-month low of $3.72 and a high of $43.73. The firm currently holds a market capitalization of $5.20 billion, a P/E ratio of -22.25, and a beta of 0.45. Financial metrics indicate a quick ratio and current ratio of 6.38, alongside a debt-to-equity ratio of 0.23. Its fifty-day moving average stands at $37.78, while the 200-day moving average is $25.58.
In related news, insider John Edward Robinson sold 90,000 shares of Cogent Biosciences on December 26, 2023, at an average price of $38.74, totalling $3,486,600. After this transaction, Robinson now owns 140,002 shares valued at approximately $5,423,677.48, reflecting a 39.13% decrease in his holdings. The sale was disclosed in a filing with the U.S. Securities and Exchange Commission (SEC).
In another notable transaction, Fairmount Funds Management LLC sold 3,500,000 shares on January 22, 2024, for an average price of $36.40, amounting to $127,400,000. Following this transaction, the director retained 5,503,418 shares, worth approximately $200,324,415.20, marking a 38.87% decrease in their position. The total insider selling over the last ninety days has reached 3,737,642 shares, valued at around $136,600,345, with insiders currently holding 7.29% of the company’s stock.
Analysts have recently reassessed their ratings for Cogent Biosciences. Wall Street Zen downgraded the company from a “hold” rating to a “sell” rating on January 31, 2024. Conversely, Jefferies Financial Group maintained a “buy” rating with a target price of $48.00 in a report released on December 8, 2023. Additionally, HC Wainwright raised its target price to $52.00 on January 6, 2024, while Needham & Company LLC reiterated a “hold” rating on the same day, December 8, 2023. Weiss Ratings also reaffirmed a “sell (e+)” rating for Cogent Biosciences on December 29, 2023.
Overall, three equities research analysts have rated the stock with a Strong Buy designation, while nine have given it a Buy rating, two have assigned a Hold rating, and one has issued a Sell rating. According to data from MarketBeat.com, the company currently holds an average rating of “Moderate Buy” and has an average price target of $39.55.
Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the development of small-molecule therapies aimed at modulating the tumor microenvironment. The firm’s research primarily targets the colony-stimulating factor 1 receptor (CSF1R), a crucial regulator of tumor-associated macrophages that may promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences seeks to restore immune surveillance and enhance the effectiveness of existing cancer treatments. The company’s lead asset is an orally bioavailable CSF1R inhibitor currently advancing through early-stage clinical trials for various solid tumors.
